Drug treatment for chronic obstructive pulmonary disease.
The aim of this article is to review therapeutic agents that are currently being developed for cardiac obstructive pulmonary disease (COPD) and examine them in the context of how they may influence disease progression. Developing disease-modifying agents for COPD has been identified as a priority by the World Health Organization, and the migration of inflammatory cells, the inflammatory response, antiproteases and mucociliary clearance have all been identified as viable targets for treating the disease.
Wark
Paul
P
University of Southampton, RCMB Centre Block Level D MP 810, Tremona Rd, Southampton, SO16 6YD, UK. p.wark@soton.ac.uk
D000818:Animals; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
D016207:Cytokines; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors